rdf:type |
|
lifeskim:mentions |
|
pubmed:issue |
1
|
pubmed:dateCreated |
2004-3-12
|
pubmed:abstractText |
The aim of this work was to evaluate the efficacy and safety of second-line treatment with weekly high-dose 5-Fluorouracil (5-FU) as a 24-hour infusion (24-h inf.) and folinic acid (FA) (AIO-regimen) plus Oxaliplatin (L-OHP) after pre-treatment with the AIO regimen, focusing in particular on the efficacy of palliative first- and second-line treatment in colorectal carcinoma (CRC).
|
pubmed:language |
eng
|
pubmed:journal |
|
pubmed:citationSubset |
IM
|
pubmed:chemical |
|
pubmed:status |
MEDLINE
|
pubmed:issn |
0250-7005
|
pubmed:author |
pubmed-author:BrücklVV,
pubmed-author:BrücklW MWM,
pubmed-author:GöhlJJ,
pubmed-author:HahnE GEG,
pubmed-author:HappichKK,
pubmed-author:HohenbergerWW,
pubmed-author:JüngertBB,
pubmed-author:LinnLL,
pubmed-author:MännleinGG,
pubmed-author:MerkelSS,
pubmed-author:SchirnerII,
pubmed-author:WeilCC
|
pubmed:issnType |
Print
|
pubmed:volume |
24
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
385-91
|
pubmed:dateRevised |
2006-11-15
|
pubmed:meshHeading |
pubmed-meshheading:15015625-Adult,
pubmed-meshheading:15015625-Aged,
pubmed-meshheading:15015625-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:15015625-Colorectal Neoplasms,
pubmed-meshheading:15015625-Drug Administration Schedule,
pubmed-meshheading:15015625-Female,
pubmed-meshheading:15015625-Fluorouracil,
pubmed-meshheading:15015625-Humans,
pubmed-meshheading:15015625-Infusions, Intravenous,
pubmed-meshheading:15015625-Leucovorin,
pubmed-meshheading:15015625-Male,
pubmed-meshheading:15015625-Middle Aged,
pubmed-meshheading:15015625-Organoplatinum Compounds,
pubmed-meshheading:15015625-Palliative Care
|
pubmed:articleTitle |
Palliative second-line treatment with weekly high-dose 5-fluorouracil as 24-hour infusion and folinic acid (AIO) plus oxaliplatin after pre-treatment with the AIO-regimen in colorectal cancer (CRC).
|
pubmed:affiliation |
Department of Internal Medicine I, University of Erlangen, Germany.
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Research Support, Non-U.S. Gov't,
Clinical Trial, Phase II
|